医学
药物基因组学
药物遗传学
甲氨蝶呤
表观遗传学
疾病
关节炎
内科学
炎性关节炎
类风湿性关节炎
青少年类风湿关节炎
生物信息学
免疫学
药理学
基因型
遗传学
基因
生物
作者
Davide Selvestrel,Marianna Lucafò,Letizia Pugnetti,Sofia Pagarin,Valentina Moressa,Serena Pastore,Andrea Taddio,Gabriele Stocco,Giuliana Decorti
标识
DOI:10.1080/1744666x.2021.1968833
摘要
Juvenile idiopathic arthritis (JIA) is a chronic disease characterized by persistent joint inflammation. JIA is the most common pediatric chronic rheumatic disease and no curative therapy is currently available. Methotrexate (MTX) is an important treatment for JIA even though a high inter-individual variability in response is observed in patients. Among the factors of this variability, genetics and epigenetics might play an important role.This review summarizes the results of pharmacogenetic and pharmacoepigenetic studies regarding MTX response in JIA. Studies considering epigenetic factors in JIA patients are still very limited, therefore this review includes also studies performed in adult patients with rheumatoid arthritis. Moreover, the relevance of biomarkers measured in blood or urine of JIA patients in relation to MTX treatment is discussed.Nowadays, even though many pharmacogenomics studies have been published, a specific genetic marker predictor of MTX efficacy or adverse events has not yet been identified. Encouraging results are available and great expectations rely on the study of epigenetics. Future studies are needed in order to identify genetic and epigenetic biomarkers that can be implemented in the clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI